Table 2.
Survival associated to administration of EGFR inhibitors in neo-RAS wt patients.
| Author, Year | Patients (n) | Best Response | Survival (Months) |
|---|---|---|---|
| Bouchada, 2021 [7] | 9 | 1 CR 4 PR 2 SD 2 PD |
PFS: 8.2 OS: 22.3 |
| Nicolazzo, 2021 [10] | 10 | NA | PFS: 10 |
| Sato, 2022 [11] | 4 | 1 PR 2 SD 1 PD |
NA |
| Osumi, 2021 [12] | 2 | 2 PR | NA |
| Osumi, 2023 [16] | 6 | 1 PR 2 SD 3 PD |
PFS: 4.8 (0.4–11.1) |
| Harada, 2023 [52] | 2 | 2 PR | PFS: 5.5 (4–7) |
| Gramaça, 2024 [47] | 4 | NA | 2nd line:
|
NA: not available; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; PFS: progression-free survival; OS: overall survival.